JP2020505334A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505334A5
JP2020505334A5 JP2019537154A JP2019537154A JP2020505334A5 JP 2020505334 A5 JP2020505334 A5 JP 2020505334A5 JP 2019537154 A JP2019537154 A JP 2019537154A JP 2019537154 A JP2019537154 A JP 2019537154A JP 2020505334 A5 JP2020505334 A5 JP 2020505334A5
Authority
JP
Japan
Prior art keywords
seq
monoclonal antibody
antibody according
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505334A (ja
JP7128191B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012479 external-priority patent/WO2018129248A1/en
Publication of JP2020505334A publication Critical patent/JP2020505334A/ja
Publication of JP2020505334A5 publication Critical patent/JP2020505334A5/ja
Priority to JP2022130651A priority Critical patent/JP7461420B2/ja
Application granted granted Critical
Publication of JP7128191B2 publication Critical patent/JP7128191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537154A 2017-01-06 2018-01-05 治療抗ＩｇＥ抗体並びにその方法及び組成物 Active JP7128191B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130651A JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130651A Division JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020505334A JP2020505334A (ja) 2020-02-20
JP2020505334A5 true JP2020505334A5 (https=) 2021-02-04
JP7128191B2 JP7128191B2 (ja) 2022-08-30

Family

ID=62789396

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537154A Active JP7128191B2 (ja) 2017-01-06 2018-01-05 治療抗ＩｇＥ抗体並びにその方法及び組成物
JP2022130651A Active JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022130651A Active JP7461420B2 (ja) 2017-01-06 2022-08-18 治療抗ＩｇＥ抗体並びにその方法及び組成物

Country Status (6)

Country Link
US (2) US11518818B2 (https=)
EP (1) EP3565587A4 (https=)
JP (2) JP7128191B2 (https=)
AU (1) AU2018205484B2 (https=)
CA (1) CA3049967C (https=)
WO (1) WO2018129248A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) * 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
HK1048127A1 (en) 2000-01-14 2003-03-21 Daiichi Pharmaceutical Co., Ltd. Novel peptide and screening method by using the same
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
WO2004070011A2 (en) * 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
US20050169909A1 (en) 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
CN102702359A (zh) * 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
JP2010532158A (ja) 2007-04-02 2010-10-07 アムジェン フレモント インク． 抗ＩｇＥ抗体
AU2008330125B2 (en) * 2007-11-21 2012-11-22 Amgen Inc. Wise binding antibodies and epitopes
AU2011333738A1 (en) * 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
KR20140119777A (ko) * 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
CN105050618B (zh) * 2012-06-21 2018-11-16 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
DK3157951T3 (da) * 2014-06-17 2020-08-17 Academia Sinica Humaniserede anti-ige-antistoffer, der tværbinder cd23 på b-lymfocytter, men ikke sensibiliserer mastceller
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR20200113228A (ko) * 2018-01-22 2020-10-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도

Similar Documents

Publication Publication Date Title
JP2019529350A5 (https=)
CN111601825A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
WO2018226580A3 (en) ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR METHODS OF USE
JP2008514618A5 (https=)
JP2011184466A5 (https=)
WO2006137931A3 (en) Human monoclonal antibodies against hendra and nipah viruses
JP2015212284A5 (https=)
CN111542546A (zh) 抗lag-3 抗体及其用途
BRPI0617485B8 (pt) anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo
HK1221964A1 (zh) 与pd-1结合的抗原结合蛋白
JP2018526970A5 (https=)
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
HRP20230197T1 (hr) Nosači za dostavu izvedeni iz omotača adenovirusnog proteina
CN114650845A (zh) 抗密蛋白抗体药物偶联物及其医药用途
WO2009074634A3 (en) Polypeptides, antibody variable domains & antagonists
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
JP2011501176A5 (https=)
EP2322551A3 (en) Compositions comprising Anti-IGF-1R Antibodies and Methods for their Production
WO2007036745A3 (en) Interleukin-13 antibody composition
JP2008508859A5 (https=)
MA32980B1 (fr) Proteines de liaison a la myostatine
WO2010018378A3 (en) Vaccine comprising amb 1 a peptides for use in the treatment of ragweed allergy
JP2020505334A5 (https=)
JP2017538412A5 (https=)
WO2005016132A3 (en) Diagnostics for sars virus